DeepMed Research

ADVENCHEN LABORATORIES, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of AL8326 in Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: AL8326 tablets

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Advenchen Laboratories, LLC

Target Recruit Count: 158

Registration Number: NCT06794957

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medicaal University, Bengbu, Anhui, China
🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
Xuancheng People´s Hospital, Xuancheng, Anhui, China

and more 7 locations

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Conditions: Sarcoma,Soft Tissue
Gynecologic Cancer

First Posted Date: 2022-11-10

Last Posted Date: 2022-11-28

Lead Sponsor: Advenchen Laboratories, LLC

Registration Number: NCT05612191

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Phase 3

Active, not recruiting

Conditions: Alveolar Soft Part Sarcoma
Synovial Sarcoma
Soft-Tissue Sarcoma
Leiomyosarcoma

Interventions: Drug: AL3818 or placebo
Drug: AL3818
Drug: Dacarbazine

First Posted Date: 2017-01-11

Last Posted Date: 2024-01-31

Lead Sponsor: Advenchen Laboratories, LLC

Target Recruit Count: 325

Registration Number: NCT03016819

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 20 locations

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Phase 3

Active, not recruiting

Conditions: Fallopian Tube Carcinoma
Cervical Carcinoma
Endometrial Carcinoma
Ovarian Carcinoma
Primary Peritoneal Carcinoma

Interventions: Drug: AL3818
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin (PLD)
Drug: Topotecan

First Posted Date: 2015-10-22

Last Posted Date: 2023-11-08

Lead Sponsor: Advenchen Laboratories, LLC

Target Recruit Count: 294

Registration Number: NCT02584478

Locations: 🇨🇳
The First Hospital of China Medical University, Shenyang, Shenyang, China
🇨🇳
Obstetrics&Gynecology Hospital of Fudan University, Shanghai, Yangpu District, China
🇨🇳
Chongqing University Cancer Hospital, Chongqing, China

and more 38 locations

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

Phase 1

Terminated

Conditions: Endometrial Cancer
Ovarian Cancer
Cervical Cancer

Interventions: Drug: AL3818

First Posted Date: 2015-09-24

Last Posted Date: 2019-06-19

Lead Sponsor: Advenchen Laboratories, LLC

Target Recruit Count: 12

Registration Number: NCT02558348

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy